Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TPIP F3 · INS-1009

Other · developed by Insmed

Phase 1 Most advanced trial (none active)
INSM Developer
1 Registered trials

What is TPIP F3?

TPIP F3 (INS1009) is an inhaled agent delivered as a capsule-based dry powder formulation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
INS-1009
Drug type
Other
Developer
Insmed Incorporated (INSM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
8GJK87S89F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07102316 Phase 1 Healthy Volunteers Completed INSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Insmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.

Follow INSM, the company behind TPIP F3

See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INSM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.